Strong commercial execution holds the key in the near term
27/08/26 -"While immense pricing and competitive pressures from Eli Lilly and compounding pharmacies have proven to be a nightmare for Novo Nordisk in the last couple of years, we are of the view that the share ..."
Pages
67
Language
English
Published on
27/08/26
You may also be interested by these reports :
27/08/26
While immense pricing and competitive pressures from Eli Lilly and compounding pharmacies have proven to be a nightmare for Novo Nordisk in the last ...
26/08/26
We upgrade Novonesis to ADD from Reduce. The Q2 26 results marked a clear inflection point: broad-based organic growth (+9%, well ahead of consensus) ...
24/08/26
Q2 profitability beat expectations; however, the top line lagged consensus. The quarterly growth was driven by strong performance in LatAm, Animal ...
21/08/26
The H1 profitability surpassed consensus, though sales matched expectations. The Branded segment was the sole driver of sales growth in H1, though ...